Oncology Hospital-to-Home (H2H) Drug Administration Market Size, Share & Trends Analysis Distribution By Therapy Type( Immunotherapy, Targeted Therapies, Maintenance Chemotherapy, Hormonal Therapy, Supportive Oncology Care, Palliative Oncology Infusions), By Service Type (Home Infusion Nursing, Home Chemotherapy Administration, Home-Based SC Oncology Injection Services, Pharmacy Compounding & Dispensing, Care Coordination & Scheduling), By Delivery Volume Capacity, By End Users and By Segments Forecasts, 2025-2034

Global Oncology Hospital-to-Home (H2H) Drug Administration Market is predicted to grow at a 14.6% CAGR during the forecast period for 2025-2034.

The oncology hospital-to-home (H2H) drug administration model is transforming cancer care by allowing treatments that were once limited to hospitals, including chemotherapy, immunotherapy, hormonal therapy, and targeted therapies, to be delivered safely within a patient’s home. This approach supports the growing need for convenient, patient-centered care that reduces the burden of frequent hospital visits while maintaining strong clinical oversight.

 Home-based oncology services enhance patient comfort, lower infection risks, and help ensure better adherence to treatment schedules. They also allow individuals to continue their daily routines, contributing to improved overall well-being during therapy. For healthcare systems, the H2H model eases hospital capacity pressures, optimizes resource utilization, and supports more cost-effective cancer care delivery. With advancements in home infusion technologies, tele-oncology platforms, remote monitoring tools, and specialized oncology nursing services, the H2H drug administration ecosystem continues to strengthen and emerge as a major growth area within the global oncology landscape.

Growing demand for patient-centric and convenient cancer care is driving the shift from hospitals to home-based treatment. Advancements in home infusion technologies, wearable devices, and remote monitoring systems are improving safety and clinical oversight. Rising healthcare costs are pushing providers and payers toward more efficient care models. The need to reduce hospital crowding and infection risk further supports adoption. Increasing availability of skilled home-care oncology nurses also strengthens H2H treatment delivery. High costs of home-infusion technologies, strict storage and handling requirements for oncology drugs, and limited access to skilled home-care oncology nurses constrain widespread adoption and slow the growth of H2H cancer care.

Competitive Landscape

Which are the Leading Players in Global Oncology Hospital-to-Home (H2H) Drug Administration?

• CareCentrix
• Naven Health
• Option Care Health
• Onco360
• Amerita
• McKesson
• Accredo
• Amber Specialty Pharmacy
• Sciensus
• Lloyds Clinical (Lloyds Pharmacy Clinical Homecare)
• CarepathRx
• BioScrip (Option Care Health legacy)
• Others

Market Dynamics

Driver

Comfortable and Personalized Care Driving Market Growth

Comfortable and personalized care is a key driver of the oncology hospital-to-home (H2H) market, as patients increasingly prefer treatment settings that reduce stress and disruption to daily life. Home-based administration offers a familiar environment, improving emotional well-being and overall treatment experience. It allows therapy schedules to be tailored to individual needs, enhancing adherence and continuity of care. Personalized monitoring tools and coordinated nursing support further ensure that patients receive timely guidance and management of side effects. Together, these benefits strengthen patient satisfaction and accelerate the shift toward home-centered oncology care.

Restrain/Challenge

High Costs of Home-Infusion Technologies

High costs of home-infusion technologies remain a major barrier to expanding oncology hospital-to-home (H2H) care. Advanced devices such as infusion pumps, wearable drug delivery systems, and remote monitoring platforms require significant investment, making them less accessible for providers and patients, especially in cost-sensitive markets. Ongoing maintenance, calibration, and training further increase expenses. These financial burdens limit the ability of healthcare systems to scale home-based oncology programs and can reduce patient access to safe, technology-supported treatment outside the hospital.

Market Segmentation:

The Global Oncology Hospital-to-Home (H2H) Drug Administration Market spans multiple therapy categories, service offerings, provider types, care models, reimbursement structures, and patient settings. By therapy type, the market includes immunotherapy, targeted therapies such as ADC-supportive regimens and subcutaneous biologics suitable for home use, maintenance chemotherapy, hormonal therapies, supportive oncology care including G-CSF options like Neulasta Onpro, anti-nausea infusion therapy, IV hydration and pain management and palliative oncology infusions. By service type, the market covers home infusion nursing, home chemotherapy administration, home-based subcutaneous oncology injection services, pharmacy compounding and dispensing, care coordination and scheduling, remote vitals monitoring and tele-oncology, patient education and toxicity management, as well as drug-delivery logistics and cold-chain support. In terms of provider type, the ecosystem includes home infusion companies, specialty oncology pharmacies, integrated health-system–led programs, and nurse-workforce management organizations.

The market also differs by case model, ranging from hospital-led home oncology programs and payer-driven value-based home cancer care to integrated oncology-at-home care teams and hybrid models combining remote oncology oversight with in-person nurse visits. From a reimbursement perspective, the sector operates through private insurance reimbursement, Medicare/Medicaid channels in the U.S., capitated contracts with hospitals, and increasing out-of-pocket or direct-pay mechanisms in emerging markets. Finally, by patient setting, oncology-at-home care includes acute oncology at home, maintenance therapies administered in the home, chronic oncology care pathways, and end-stage or palliative home-based oncology services.
Targeted therapy dominates the oncology hospital-to-home (H2H) drug administration market because these treatments are highly precise, better tolerated, and increasingly designed for home-friendly delivery formats. Unlike traditional chemotherapy, targeted agents act on specific cancer pathways, resulting in fewer severe side effects and reducing the need for constant hospital supervision. Many targeted therapies are available as oral drugs, subcutaneous injections, or infusions suitable for home administration, making them ideal for remote care models. Their strong clinical outcomes, expanding indications, and growing use in personalized medicine further strengthen their market leadership.

Home Infusion Nursing is the Highest-Growing Segment in the H2H Oncology Market

Home infusion nursing is the fastest-growing segment in the H2H oncology market because it provides the clinical foundation needed to safely deliver complex cancer treatments outside the hospital. Skilled nurses manage drug preparation, infusion administration, side-effect monitoring, and patient education during each visit, ensuring high safety and adherence levels. Their involvement increases physician and patient confidence in home-based care, especially for therapies requiring close oversight. As demand for convenient cancer treatment rises and hospitals face staffing and capacity pressures, professionally supervised home infusions become essential, driving rapid segment expansion.

Why North America Led the Global Oncology Hospital-To-Home (H2H) Drug Administration Market?

North America leads the hospital-to-home cancer drug administration market because the region has strong home-health services, skilled nurses, and dependable delivery systems that make it easy and safe to give cancer treatments at home.

People and doctors in the U.S. and Canada are comfortable with home-based care, and insurance plans support it because it helps lower hospital costs. This creates a well-organized system where home cancer treatment grows faster than in other regions. COVID-19 also boosted the market, as more patients chose safer care at home instead of visiting crowded hospitals.

Key Development :

•    In Dec 2025, Regeneron announced that its new therapy a bispecific-antibody called odronextamab combined with chemotherapy showed 100% complete response rate in a small trial of patients with a type of blood cancer called Diffuse Large B Cell Lymphoma (DLBCL). his approach delivers immediate and complete B-cell depletion at the 160 mg starting dose, demonstrating a compelling early signal of efficacy that strengthens the therapy’s strategic positioning for future market differentiation and clinical adoption
•    In September 2025, BioNTech and Bristol Myers Squibb reported early positive results for their new cancer drug pumitamig in advanced small-cell lung cancer. Tested with chemotherapy, it shows promising results but still needs more studies to confirm safety and effectiveness.;

Oncology Hospital-to-Home (H2H) Drug Administration Market Report Scope: